Zobrazeno 1 - 10
of 90
pro vyhledávání: '"SFM-DR"'
Autor:
Xu, Xuefen1,2 (AUTHOR) 460103@njucm.edu.cn, Ji, Shufan2 (AUTHOR), Chen, Yuan1 (AUTHOR), Xia, Siwei2 (AUTHOR), Li, Yang2 (AUTHOR), Chen, Li2 (AUTHOR), Li, Yujia2 (AUTHOR), Zhang, Feng2 (AUTHOR), Zhang, Zili2 (AUTHOR), Zheng, Shizhong2 (AUTHOR) nytws@njucm.edu.cn
Publikováno v:
Cell Communication & Signaling. 3/3/2023, Vol. 21 Issue 1, p1-17. 17p.
Autor:
Tomalika Rahmat Ullah
Publikováno v:
Journal of Bone Oncology
Journal of Bone Oncology, Vol 17, Iss, Pp-(2019)
Journal of Bone Oncology, Vol 17, Iss, Pp-(2019)
CXCR4 is a pleiotropic chemokine receptor which acts through its ligand CXCL12 to regulate diverse physiological processes. CXCR4/CXCL12 axis plays a pivotal role in proliferation, invasion, dissemination and drug resistance in multiple myeloma (MM).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2aef32d7c524945afc1fdd274518216
http://europepmc.org/articles/PMC6658931
http://europepmc.org/articles/PMC6658931
Publikováno v:
Canadian Journal of Chemical Engineering; Dec2018, Vol. 96 Issue 12, p2564-2574, 11p
Autor:
Ralf Jesenofsky, Stephan L. Haas, Cornelius Weidenauer, Wolfgang Hagmann, J.-Matthias Löhr, Ralf Faissner, Rainer Heuchel, Patrick Michl, Marvin Schober
Publikováno v:
Cancers, Vol 6, Iss 4, Pp 2137-2154 (2014)
Cancers
Cancers
Pancreatic ductal adenocarcinoma (PDAC) occurs mainly in people older than 50 years of age. Although great strides have been taken in treating PDAC over the past decades its incidence nearly equals its mortality rate and it was quoted as the 4th lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e3380e0ab956c789fc8c1db22f986b9
http://www.mdpi.com/2072-6694/6/4/2137
http://www.mdpi.com/2072-6694/6/4/2137
Publikováno v:
Archives of Toxicology; Jan2015, Vol. 89 Issue 1, p121-136, 16p
Autor:
Xuefen Xu, Shufan Ji, Yuan Chen, Siwei Xia, Yang Li, Li Chen, Yujia Li, Feng Zhang, Zili Zhang, Shizhong Zheng
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background The most significant cause of treatment failure in chronic myeloid leukemia (CML) is a persistent population of minimal residual cells. Emerging evidences showed that methylation of SHP-1 contributed to Imatinib (IM) resistance. B
Externí odkaz:
https://doaj.org/article/9b9d14751a1644138f118543d9e88c58
Autor:
Said, Georges1, Guilbert, Marie1, Morjani, Hamid1, Garnotel, Roselyne2, Jeannesson, Pierre1, Btaouri, Hassan El3 hassan.elbtaouri@univ-reims.fr
Publikováno v:
Chemotherapy Research & Practice. 2012, p1-10. 10p. 3 Diagrams, 1 Chart, 2 Graphs.
Autor:
Kozalak, Gül1,2 (AUTHOR) gul.kozalak@sabanciuniv.edu, Bütün, İsmail1 (AUTHOR), Toyran, Erçil1 (AUTHOR), Koşar, Ali1,2,3 (AUTHOR) gul.kozalak@sabanciuniv.edu
Publikováno v:
Pharmaceuticals (14248247). Jan2023, Vol. 16 Issue 1, p111. 22p.
Autor:
Huynh, Mailee1,2 (AUTHOR), Chang, Hae Yeun1,2 (AUTHOR), Lisiero, Dominique N.1,2 (AUTHOR), Ong, Irene M.3,4 (AUTHOR), Kashyap, Trinayan5 (AUTHOR), Callander, Natalie S.6 (AUTHOR), Miyamoto, Shigeki1,2,4 (AUTHOR) smiyamot@wisc.edu
Publikováno v:
PLoS ONE. 12/08/2022, Vol. 17 Issue 12, p1-18. 18p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.